A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
Clinical trial NCT07602777 · RECRUITING
Trial details
- NCT number
- NCT07602777
- Sponsor
- GlaxoSmithKline
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-22
- Primary completion
- 2027-11-18
- Enrollment
- 113
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.